SCHEMBL23792271

SCHEMBL23792271

CC(C)c1sc(Nc2ncc(C(F)(F)F)cc2C(=O)O)nc1-c1ccc(-c2cccs2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.42
▸ ALDH1A1 P00352 6/20 0.42
▸ ACLY P53396 1/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.39
▸ NFKB1 P19838 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ JUN P05412 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ S1PR2 O95136 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CTSC P53634 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ CACNA1B Q00975 1/20 0.36
▸ APBA1 Q02410 1/20 0.36
▸ DHODH Q02127 4/20 0.36
▸ SORT1 Q99523 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23792226 0.93 KDM4E (0.45) KDM4EALDH1A1ACLYNPSR1NFKB1
SCHEMBL23792231 0.91 SORT1 (0.42) KDM4EALDH1A1NFKB1MEN1KMT2A
SCHEMBL23792235 0.87 PTGDR2 (0.41) KDM4EALDH1A1ACLYNPSR1NFKB1
SCHEMBL30295521 0.86 KDM4E (0.42) KDM4EALDH1A1ACLYNPSR1NFKB1
SCHEMBL26479111 0.86 KDM4E (0.42) KDM4EALDH1A1ACLYNPSR1NFKB1
SCHEMBL23792228 0.84 SORT1 (0.38) KDM4EALDH1A1NPSR1NFKB1GAA
SCHEMBL23792273 0.84 SORT1 (0.38) KDM4EALDH1A1SORT1
SCHEMBL23782530 0.84 KDM4E (0.42) KDM4EALDH1A1ACLYNPSR1NFKB1
SCHEMBL23792008 0.84 DHODH (0.39) ACLYNFKB1JUNNFKB2RELA
SCHEMBL25545830 0.83 MAPT (0.38) KDM4EALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 KDM4E 710/4885ALDH1A1 4776/4885ACLY 3152/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 KDM4E 710/4885ALDH1A1 4776/4885ACLY 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback